LAUSR

Graphical abstract Figure. No Caption available. HighlightsNAC shows anxiolytic effects on five mice models of anxiety.Subacute NAC results in lower effective anxiolytic doses than acute treatment.Anxiolytic doses of NAC do not affect locomotion. ABSTRACT Anxiety disorders are highly prevalent and often result in poor quality of life. Available anxiolytics show significant adverse effects as well as partial efficacy in a sizable part of patients. Innovative treatments with more favorable risk‐benefit ratio are sorely needed. A growing body of clinical data indicates the benefits of N‐acetylcysteine (NAC) in psychiatric conditions. NAC modulates antioxidant, glutamatergic, inflammatory and neurotrophic pathways in the central nervous system, all of which are relevant to anxiety pathology. We evaluated the effects of NAC in mice models commonly used to characterize anxiolytic compounds. Male adult CF1 or BALB/c mice were treated (i.p.) acutely or subacutely (4 consecutive days) with NAC (60–150 mg/kg) 60 min before open field, light/dark, hole‐board, social interaction, elevated T‐maze or stress‐induced hyperthermia tests. Diazepam (2 mg/kg) was used as positive control. We found that NAC presents anxiolytic effects in all models, except for the elevated T‐maze. Subacute treatments resulted in lower effective doses in comparison to acute treatment. The anxiolytic effects of NAC were comparable to diazepam. NAC is a safe and low cost medicine with suggested benefits in psychiatric conditions often presenting co‐morbidity with anxiety. This study contributes evidence to support the validity of clinical trials with NAC in the context of anxiety disorders, especially considering the safety profile in comparison to the limitations of diazepam for long term treatment.